Ebixa dosing made easier

Ebixa (memantine) is now licensed for once-daily administration in the treatment of patients with moderate to severe Alzheimer's disease.

A new 20mg tablet has been added to the Ebixa range to simplify the once-daily administration and a new treatment initiation pack has been launched to aid titration.

View Ebixa drug record

Further information: Lundbeck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New guidance for minimising psychological impact of COVID-19 pandemic in primary care patients
Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

MIMS launches Respiratory and Allergy Learning webinars

MIMS launches Respiratory and Allergy Learning webinars

Join us for the 2020 Respiratory and Allergy Learning...